Table 1.

Patient and clinical characteristics


Characteristic

All patients

DLI
Total no. of patients studied   446   53  
Median age, y (range)   54 (5-74)   56 (24-72)  
Sex, no. M/F   285/161   42/11  
Sibling donor/unrelated donor, no. patients   306/140   52/1  
Graft source, PBSC/BM, no. patients   426/20   53/0  
Conditioning, no. patients   
    TBI only   112   32  
    Fludarabine/TBI   334   21  
Disease, no. patients   
    MM   106   9  
    NHL   76   4  
        Follicular   10   0  
        High grade   28   2  
        Mantle cell   21   0  
        Other   17   2  
    MDS   69   10  
    AML   55   9  
    CLL   37   6  
    CML   37   5  
    HD   24   5  
    ALL   12   1  
    Myeloproliferative disorders   9   0  
    Renal carcinoma   13   2  
    Cervical carcinoma   2   0  
    Breast carcinoma   2   1  
    Osteosarcoma   1   0  
    Melanoma   3   1  
Median time to DLI from transplantation, d (range)   —   99 (48-1228)  
Median follow-up from DLI for patients alive, mo (range)
 

 
30 (4-59)
 

Characteristic

All patients

DLI
Total no. of patients studied   446   53  
Median age, y (range)   54 (5-74)   56 (24-72)  
Sex, no. M/F   285/161   42/11  
Sibling donor/unrelated donor, no. patients   306/140   52/1  
Graft source, PBSC/BM, no. patients   426/20   53/0  
Conditioning, no. patients   
    TBI only   112   32  
    Fludarabine/TBI   334   21  
Disease, no. patients   
    MM   106   9  
    NHL   76   4  
        Follicular   10   0  
        High grade   28   2  
        Mantle cell   21   0  
        Other   17   2  
    MDS   69   10  
    AML   55   9  
    CLL   37   6  
    CML   37   5  
    HD   24   5  
    ALL   12   1  
    Myeloproliferative disorders   9   0  
    Renal carcinoma   13   2  
    Cervical carcinoma   2   0  
    Breast carcinoma   2   1  
    Osteosarcoma   1   0  
    Melanoma   3   1  
Median time to DLI from transplantation, d (range)   —   99 (48-1228)  
Median follow-up from DLI for patients alive, mo (range)
 

 
30 (4-59)
 

PBSC indicates peripheral blood stem cells; BM, bone marrow; and —, not applicable.

Close Modal

or Create an Account

Close Modal
Close Modal